MCID: ANS011
MIFTS: 55

Anus Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Anus Cancer

MalaCards integrated aliases for Anus Cancer:

Name: Anus Cancer 11 14
Anal Cancer 11 19 41 75
Malignant Neoplasm of Anus 71
Malignant Anal Tumor 11
Cancer of the Anus 19
Anus Neoplasms 71
Anal Carcinoma 71

Classifications:



External Ids:

Disease Ontology 11 DOID:14110
ICD9CM 34 154.2 154.3
NCIt 49 C7379
SNOMED-CT 68 93669004 93676009
ICD10 31 C21.0 C21.1
UMLS 71 C0003463 C0153445 C0153446 more

Summaries for Anus Cancer

MedlinePlus: 41 The anus is where stool leaves your body when you go to the bathroom. It is made up of your outer layers of skin and the end of your large intestine. Anal cancer is a disease in which cancer cells form in the tissues of the anus. Anal cancer is rare. It is more common in smokers and people over 50. You are also at higher risk if you have HPV, have anal sex, or have many sexual partners. Symptoms include bleeding, pain, or lumps in the anal area. Anal itching and discharge can also be signs of anal cancer. Doctors use tests that examine the anus to diagnose anal cancer. They include a physical exam, endoscopy, ultrasound, and biopsy. Treatments include radiation therapy, chemotherapy, and surgery. NIH: National Cancer Institute

MalaCards based summary: Anus Cancer, also known as anal cancer, is related to human papillomavirus infectious disease and squamous cell carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Anus Cancer is CD4 (CD4 Molecule), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Octreotide and Cemiplimab have been mentioned in the context of this disorder. Affiliated tissues include anus, lymph node and skin, and related phenotypes are Decreased viability and homeostasis/metabolism

GARD: 19 Anal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the anus. Ssymptoms of the condition include rectal bleeding; a lump in or near the anus; anal pain; itching; changes in bowel habits; and/or swollen lymph nodes. In most cases, the underlying cause of Anal cancer is unknown. There appears to be a link between Anal cancer and the human papillomavirus (HPV) infection. Other risk factors for Anal cancer include HIV infection, sexual activity, smoking, and a weakened immune system.

Disease Ontology: 11 A large intestine cancer that is located in the anus.

Wikipedia: 75 Anal cancer is a cancer which arises from the anus, the distal opening of the gastrointestinal tract.... more...

Related Diseases for Anus Cancer

Diseases related to Anus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 760)
# Related Disease Score Top Affiliating Genes
1 human papillomavirus infectious disease 30.9 TP53 PIK3CA HRAS GP5 EGFR CTLA4
2 squamous cell carcinoma 30.9 TP53 PIK3CA KRT7 KRAS HRAS EGFR
3 papilloma 30.7 UBE3A TP53 KRT7 KRAS EGFR CDKN2A
4 syphilis 30.7 CD8A CD4 CCR6
5 crohn's disease 30.7 H2AC18 CD8A CD4 CCR6
6 rectum cancer 30.6 TP53 KRAS HRAS H2AC18 EGFR CCR6
7 rectal benign neoplasm 30.5 TP53 PIK3CA KRT7 KRAS HRAS EGFR
8 anal squamous cell carcinoma 30.5 ZNF582 WDR17 TP53 PIK3CA KRT7 H2AC18
9 immune deficiency disease 30.4 PDCD1 H2AC18 CTLA4 CD8A CD4 CCR6
10 basaloid squamous cell carcinoma 30.4 TP53 KRT7 CDKN2A
11 anal canal adenocarcinoma 30.4 KRT7 CAGE1
12 cervical cancer 30.3 UBE3A TP53 PIK3CA HRAS CDKN2A
13 anogenital venereal wart 30.3 UBE3A TP53 H2AC18 GP6 GP5 CDKN2A
14 deficiency anemia 30.2 TP53 H2AC18 CD8A CD4 CCR6
15 lymphatic system disease 30.2 TP53 H2AC18 CD8A CD4 CCR6
16 thrombocytopenia 30.2 PDCD1 GP6 GP5 CTLA4 CD4 CD274
17 adenocarcinoma 30.2 TP53 PIK3CA KRT7 KRAS HRAS EGFR
18 cellulitis 30.2 CD8A CD4 CCR6
19 suppressor of tumorigenicity 3 30.2 UBE3A TP53 CDKN2A
20 lymphoma 30.2 TP53 PDCD1 EGFR CDKN2A CD274 CCR6
21 telangiectasis 30.1 TP53 H2AC18 CCR6
22 urinary tract infection 30.1 H2AC18 CD4 CCR6
23 hepatitis a 30.1 PDCD1 CTLA4 CD4
24 appendiceal neoplasm 30.1 KRT7 KRAS HRAS
25 lymph node disease 30.1 H2AC18 CD8A CD4 CCR6
26 verrucous carcinoma 30.1 TP53 PIK3CA GP5 EGFR CDKN2A
27 penile benign neoplasm 30.0 TP53 PIK3CA GP5 CDKN2A CD274
28 basal cell carcinoma 30.0 TP53 KRT7 H2AC18 EGFR CDKN2A CCR6
29 appendix adenocarcinoma 30.0 TP53 KRT7 KRAS HRAS
30 adenosquamous carcinoma 29.9 KRT7 KRAS HRAS EGFR
31 vulva cancer 29.9 ZNF582 TP53 PIK3CA KRT7 HRAS GP5
32 lymphoma, non-hodgkin, familial 29.8 TP53 PIK3CA H2AC18 CTLA4 CD8A CD4
33 human immunodeficiency virus infectious disease 29.8 PDCD1 H2AC18 CD8A CD4 CCR6
34 mucinous adenocarcinoma 29.8 TP53 PIK3CA KRT7 KRAS HRAS EGFR
35 alcohol use disorder 29.8 H2AC18 CD4 CCR6
36 cervix uteri carcinoma in situ 29.8 ZNF582 TP53 GP6 GP5 CDKN2A CD4
37 toxic encephalopathy 29.7 TP53 H2AC18 CCR6
38 squamous cell carcinoma, head and neck 29.7 TP53 PIK3CA HRAS H2AC18 EGFR CDKN2A
39 viral infectious disease 29.6 PDCD1 H2AC18 CTLA4 CD4 CD274 CCR6
40 adenoid cystic carcinoma 29.6 TP53 PIK3CA KRT7 KRAS HRAS EGFR
41 myelodysplastic syndrome 29.5 TP53 KRAS HRAS H2AC18 CDKN2A CD8A
42 vaginal cancer 29.5 UBE3A TP53 KRT7 HRAS GP5 EGFR
43 endometrial cancer 29.4 TP53 PIK3CA KRT7 KRAS HRAS H2AC18
44 colorectal adenocarcinoma 29.3 TP53 PIK3CA KRT7 KRAS HRAS H2AC18
45 oropharynx cancer 29.3 UBE3A TP53 PIK3CA KRT7 HRAS H2AC18
46 penile cancer 29.2 UBE3A TP53 PIK3CA GP6 GP5 EGFR
47 gastrointestinal stromal tumor 29.2 TP53 PIK3CA KRAS HRAS H2AC18 EGFR
48 melanoma 29.2 TP53 PIK3CA PDCD1 KRAS HRAS CTLA4
49 colonic benign neoplasm 29.1 TP53 PIK3CA KRT7 KRAS HRAS H2AC18
50 peripheral nervous system disease 29.1 TP53 KRAS HRAS H2AC18 EGFR CTLA4

Comorbidity relations with Anus Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia

Graphical network of the top 20 diseases related to Anus Cancer:



Diseases related to Anus Cancer

Symptoms & Phenotypes for Anus Cancer

UMLS symptoms related to Anus Cancer:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; pruritus ani; gastrointestinal gas

GenomeRNAi Phenotypes related to Anus Cancer according to GeneCards Suite gene sharing:

25 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.34 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.34 EGFR HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.34 KRAS
4 Decreased viability GR00106-A-0 10.34 KRAS
5 Decreased viability GR00221-A-1 10.34 CDKN2A EGFR HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.34 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.34 CDKN2A HRAS
8 Decreased viability GR00221-A-4 10.34 CDKN2A EGFR PIK3CA
9 Decreased viability GR00301-A 10.34 KRAS
10 Decreased viability GR00381-A-1 10.34 KRAS
11 Decreased viability GR00402-S-2 10.34 PIK3CA
12 no effect GR00402-S-1 10.17 CAGE1 CCR6 CD274 CD4 CD8A CDKN2A
13 no effect GR00402-S-2 10.17 CAGE1 CCR6 CD274 CD4 CDKN2A CTLA4

MGI Mouse Phenotypes related to Anus Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 CCR6 CD274 CD4 CDKN2A CTLA4 EGFR
2 no phenotypic analysis MP:0003012 10.06 CD274 CD4 CDKN2A EGFR HRAS KRAS
3 endocrine/exocrine gland MP:0005379 10.06 CD4 CD8A CDKN2A CTLA4 EGFR HRAS
4 neoplasm MP:0002006 9.98 CDKN2A EGFR HRAS KRAS PDCD1 PIK3CA
5 immune system MP:0005387 9.93 CCR6 CD274 CD4 CD8A CDKN2A CTLA4
6 digestive/alimentary MP:0005381 9.86 CD4 CDKN2A CTLA4 EGFR HRAS KRAS
7 skeleton MP:0005390 9.7 CD274 CDKN2A CTLA4 EGFR GP6 HRAS
8 integument MP:0010771 9.4 CD274 CD4 CD8A CDKN2A CTLA4 EGFR

Drugs & Therapeutics for Anus Cancer

Drugs for Anus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
2
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
3
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
4
Ipilimumab Approved Phase 3 477202-00-9
5
Calcium polycarbophil Approved Phase 3 126040-58-2
6
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
7
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
8
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
9
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 5702198 441203
10
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
11
Mitomycin Approved Phase 2, Phase 3 50-07-7 5746
12 Immunosuppressive Agents Phase 3
13 Alkylating Agents Phase 3
14 Gastrointestinal Agents Phase 3
15 Antineoplastic Agents, Hormonal Phase 3
16 Psyllium Phase 3
17 Immunologic Factors Phase 3
18 Immune Checkpoint Inhibitors Phase 3
19 Adjuvants, Immunologic Phase 3
20 interferons Phase 3
21 Anesthetics Phase 3
22 Vaccines Phase 3
23 Albumin-Bound Paclitaxel Phase 3
24 Antimitotic Agents Phase 3
25 Tubulin Modulators Phase 3
26 Antimetabolites Phase 2, Phase 3
27 Anti-Bacterial Agents Phase 2, Phase 3
28 Antibiotics, Antitubercular Phase 2, Phase 3
29
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
30
Cidofovir Approved Phase 2 113852-37-2 60613
31
Panitumumab Approved, Investigational Phase 1, Phase 2 339177-26-3
32
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
33
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
34
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
35
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
36
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 2 62-33-9, 60-00-4 6049
37
Pentetic acid Approved Phase 2 67-43-6
38
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
39
Avelumab Approved, Investigational Phase 2 1537032-82-8
40
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
41
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
42
Durvalumab Approved, Investigational Phase 2 1428935-60-7
43
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
44
Pomalidomide Approved Phase 2 19171-19-8 134780
45
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
46
Cetuximab Approved Phase 2 205923-56-4
47
Palonosetron Approved, Investigational Phase 2 119904-90-4, 135729-56-5 148211 6337614
48
Manganese Approved, Nutraceutical Phase 1, Phase 2 7439-96-5 27854
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
50
Entinostat Investigational Phase 1, Phase 2 209783-80-2 4261

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Unknown status NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
2 Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
3 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women Completed NCT01651949 Phase 3
4 Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study Completed NCT00003652 Phase 3 cisplatin;fluorouracil
5 A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
6 A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate
7 A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults Completed NCT01164722 Phase 3
8 A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Na�ve Metastatic Anal Cancer Patients Recruiting NCT04444921 Phase 3 Carboplatin;Paclitaxel
9 Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
10 A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma Recruiting NCT05374252 Phase 3 PD-1 inhibitor
11 Reliability of Indocyanine Green Use in Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
12 Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA) Recruiting NCT04534075 Phase 3
13 A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer Active, not recruiting NCT03233711 Phase 3
14 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Active, not recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
15 A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age. Active, not recruiting NCT04635423 Phase 3
16 Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Mitomycins
17 Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
18 An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
19 Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer Unknown status NCT03381352 Phase 2 Capecitabine;Mitomycin C
20 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Unknown status NCT03302858 Phase 2
21 Randomized Phase 2 Trial of Cetuximab and Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment Unknown status NCT03944252 Phase 2 Avelumab;Cetuximab
22 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Prospective, Phase II Trial Assessing Acute Toxicities Rates Compared to Historic Controls Treated With Volumetric Modulated Arc Therapy (VMAT) Completed NCT03690921 Phase 2 Cisplatin;Fluorouracil
23 A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
24 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
25 Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women Completed NCT00550589 Phase 2 cidofovir
26 A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
27 A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals Completed NCT00052897 Phase 1, Phase 2
28 Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal Completed NCT02399813 Phase 2 ADXS11-001
29 Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma Completed NCT00324415 Phase 2 cisplatin;fluorouracil
30 Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma Completed NCT00316888 Phase 2 cisplatin;fluorouracil
31 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
32 AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males Completed NCT01209325 Phase 2
33 A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men Completed NCT00428285 Phase 2
34 Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream Completed NCT00622440 Phase 2 AIJP (Arnebia Indigo Jade Pearl);Placebo
35 Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging Completed NCT01717391 Phase 2 fluorothymidine F 18
36 Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma. Completed NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
37 Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus Completed NCT01581840 Phase 1, Phase 2 radiochemotherapy;Panitumumab
38 A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Completed NCT03499795 Phase 2
39 Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
40 Risk-Adapted Therapy for HIV-Associated Anal Cancer Recruiting NCT04929028 Phase 2 Capecitabine;Fluorouracil;Mitomycin
41 Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes Recruiting NCT04907643 Phase 2
42 Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. Recruiting NCT04230759 Phase 2 Chemotherapy;Durvalumab
43 ReRad III. Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy Recruiting NCT05055635 Phase 2
44 A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Recruiting NCT04166318 Phase 2 Capecitabine;Fluorouracil;Mitomycin
45 A Phase 1 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001 Recruiting NCT03386500 Phase 1, Phase 2 BMX-001
46 ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer Recruiting NCT05438836 Phase 2
47 A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
48 Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Recruiting NCT04287868 Phase 1, Phase 2
49 A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Recruiting NCT04708470 Phase 1, Phase 2 Bintrafusp Alfa;NHS-IL12;Entinostat
50 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) Recruiting NCT02628067 Phase 2

Search NIH Clinical Center for Anus Cancer

Genetic Tests for Anus Cancer

Anatomical Context for Anus Cancer

Organs/tissues related to Anus Cancer:

FMA: Anus
MalaCards : Lymph Node, Skin, T Cells, Cervix, Colon, Prostate, Lung

Publications for Anus Cancer

Articles related to Anus Cancer:

(show top 50) (show all 2652)
# Title Authors PMID Year
1
Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer. 62 41
36402828 2022
2
"The problem is that our culture is just so messed up about aging." Recruiting older men who have sex with men (MSM) into research studies: an example from a study of aging, HIV, and anal HPV. 62 41
36401159 2022
3
Workplace violence at emergency departments, Ain Shams University Hospitals, Cairo, Egypt. 41
36443795 2022
4
Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors. 62
36274448 2023
5
Prostrate After Prostate? Recommend Attempt for Definitive Treatment of Oligometastatic Anal Cancer After Low Dose Rate Brachytherapy. 62
36395800 2022
6
Sowing the Seeds: A Case of Oligometastatic Anal Cancer 12 Years After Prostate Brachytherapy. 62
36395797 2022
7
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529. 62
36413683 2022
8
Effect of the environment on home-based self-sampling kits for anal cancer screening. 62
36096333 2022
9
Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy. 62
36102865 2022
10
A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study. 62
36126275 2022
11
HPV-Associated Anal Cancer Knowledge, Attitudes, and Health Communication Behaviors Among Non-clinical Providers at HIV/AIDS Service Organizations in Southern United States Region. 62
34148218 2022
12
A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups. 62
35793241 2022
13
A pilot study investigating the role of 18 F-FDG-PET in the early identification of chemoradiotherapy response in anal cancer. 62
35906833 2022
14
Comparison of four assays for human papillomavirus detection in the anal canal. 62
35809783 2022
15
Artificial intelligence and high-resolution anoscopy: automatic identification of anal squamous cell carcinoma precursors using a convolutional neural network. 62
35986806 2022
16
Identifying Predictors of Anal HPV Status in HPV-Vaccinated MSM: A Machine Learning Approach. 62
36332152 2022
17
Radiological incidence of donor-site incisional hernia and parastomal hernia after vertical rectus abdominus myocutaneous flap-based reconstruction following colorectal surgery. 62
36328985 2022
18
Prevalence and Predictors of High-Grade Anal Dysplasia in People With HIV in One Southeastern Ryan White HIV/AIDS Program Clinic. 62
36467302 2022
19
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer. 62
36455685 2022
20
Successful Management of Anal Squamous Cell Carcinoma With Liver and Ovary Metastases: A Case Report. 62
36309369 2022
21
Conventional cytologic diagnosis of human papillomavirus-induced anal intraepithelial neoplasia: The experience of a referral center in Rio de Janeiro, Brazil. 62
36398627 2022
22
International validation of the EORTC QLQ-ANL27, a field study to test the anal cancer-specific health-related quality of life questionnaire. 62
36402360 2022
23
The effect of recombinant human epidermal growth factor on radiation dermatitis in rectal and anal cancer patients: a self-controlled study. 62
36335306 2022
24
Overview of Radiation Treatment Volume Variations in Anal Cancer Contouring Guidelines. 62
35718076 2022
25
Challenges and controversies patients and (health care) professionals experience in managing vaginal, vulvar, penile or anal cancer: The SILENCE study. 62
35938519 2022
26
Online adaptive radiotherapy of anal cancer: Normal tissue sparing, target propagation methods, and first clinical experience. 62
36174846 2022
27
One-Drop Serum Screening Test for Anal Cancer in Men via Infrared Attenuated Total Reflection Spectroscopy. 62
36197692 2022
28
Patients with Anal Cancer Have Low Functional and High Symptomatic Health-Related Quality of Life Scores After Chemoradiation. 62
36369421 2022
29
HPV status and HPV16 viral load in anal cancer and its association with clinical outcome. 62
35785486 2022
30
ASO Visual Abstract: Intraoperative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry. 62
36224512 2022
31
Prevention of human papillomavirus-related anal cancer in women living with human immunodeficiency virus. 62
36196561 2022
32
Intra-operative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry. 62
36255512 2022
33
[Anal cancer: Focus on current treatment and future perspective]. 62
36008262 2022
34
High dose rate brachytherapy for anal cancer: A review of a systematic review. 62
35964764 2022
35
External validation of a composite bio-humoral index in anal cancer patients undergoing concurrent chemoradiation. 62
36273737 2022
36
Primary Anal Cancer Screening Results from 381 Women Living with Human Immunodeficiency Virus. 62
36196502 2022
37
Linguistic validation of the Spanish version of the Anal Cancer High-Grade squamous intraepithelial lesions outcomes Research Health-Related Symptom Index (A-HRSI): AMC-A04. 62
36219358 2022
38
The emerging role of immunotherapy in the treatment of anal cancer. 62
36334330 2022
39
Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus. 62
35325073 2022
40
Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience. 62
36269537 2022
41
CROI 2022: tuberculosis and infectious complications in persons With HIV. 62
36347059 2022
42
A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer. 62
35657350 2022
43
Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis. 62
35990580 2022
44
CROI 2022: metabolic and other complications of HIV infection or COVID-19. 62
36347058 2022
45
Update to the structured MRI report for primary staging of rectal cancer : Perspective from the SAR Disease Focused Panel on Rectal and Anal Cancer. 62
35881198 2022
46
Concurrent anorectal and cervical cytology in women with positive and negative cervical smear test results: A cross-sectional study. 62
36183298 2022
47
[Human Papillomavirus: screening of cervical and anal cancers]. 62
36259700 2022
48
Cytology and LGBT+ health: establishing inclusive cancer screening programs. 62
35840516 2022
49
"Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC). 62
35346604 2022
50
Evaluating the cascade of care for anal cancer screening within a Ryan White HIV/AIDS Program clinic. 62
35833535 2022

Variations for Anus Cancer

Expression for Anus Cancer

Search GEO for disease gene expression data for Anus Cancer.

Pathways for Anus Cancer

Pathways related to Anus Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 UBE3A TP53 PIK3CA PDCD1 KRAS HRAS
2
Show member pathways
13.79 TP53 PIK3CA PDCD1 KRAS HRAS H2AC18
3
Show member pathways
13.43 UBE3A PIK3CA PDCD1 KRAS HRAS CTLA4
4
Show member pathways
12.92 TP53 PIK3CA HRAS EGFR CDKN2A CD4
5
Show member pathways
12.91 TP53 KRAS HRAS CTLA4 CD8A CD4
6
Show member pathways
12.86 PIK3CA KRAS HRAS CD4 CCR6
7 12.84 PIK3CA KRAS HRAS EGFR CD274
8
Show member pathways
12.66 CD4 EGFR HRAS KRAS TP53
9
Show member pathways
12.55 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
10 12.49 TP53 PIK3CA HRAS EGFR CDKN2A CD274
11
Show member pathways
12.42 TP53 PIK3CA KRAS HRAS EGFR
12
Show member pathways
12.41 PIK3CA KRAS HRAS EGFR
13 12.4 EGFR HRAS KRAS TP53
14
Show member pathways
12.38 CD4 EGFR HRAS KRAS PIK3CA TP53
15
Show member pathways
12.37 TP53 PIK3CA KRAS HRAS EGFR
16
Show member pathways
12.36 TP53 PIK3CA KRAS HRAS EGFR
17
Show member pathways
12.32 PIK3CA KRAS HRAS CD4
18 12.25 EGFR HRAS KRAS PIK3CA
19
Show member pathways
12.24 PIK3CA KRAS HRAS EGFR
20
Show member pathways
12.21 PIK3CA KRAS HRAS GP6
21
Show member pathways
12.19 TP53 PIK3CA KRAS HRAS EGFR
22 12.17 TP53 PIK3CA KRAS HRAS
23
Show member pathways
12.11 PIK3CA PDCD1 CTLA4 CD8A CD4 CD274
24
Show member pathways
12.08 EGFR HRAS KRAS PIK3CA
25
Show member pathways
12.06 PIK3CA KRAS HRAS EGFR
26
Show member pathways
12.03 PIK3CA KRAS HRAS EGFR
27
Show member pathways
11.96 PIK3CA KRAS HRAS EGFR
28
Show member pathways
11.84 PIK3CA KRAS HRAS
29 11.83 TP53 PIK3CA KRAS HRAS
30 11.82 TP53 PIK3CA HRAS
31 11.8 CD8A CD4 CCR6
32
Show member pathways
11.8 EGFR HRAS KRAS PIK3CA
33
Show member pathways
11.79 PIK3CA KRAS HRAS
34
Show member pathways
11.78 PDCD1 CD4 CD274
35 11.77 PIK3CA KRAS HRAS EGFR CDKN2A
36
Show member pathways
11.76 PIK3CA KRAS HRAS
37 11.67 TP53 PIK3CA HRAS
38
Show member pathways
11.66 PIK3CA KRAS HRAS
39 11.65 UBE3A TP53 CDKN2A
40
Show member pathways
11.65 UBE3A KRAS HRAS
41
Show member pathways
11.63 TP53 PIK3CA KRAS HRAS
42 11.62 KRAS HRAS EGFR
43
Show member pathways
11.57 PIK3CA KRAS HRAS
44 11.53 PDCD1 CTLA4 CD274
45 11.47 KRAS HRAS EGFR
46
Show member pathways
11.41 TP53 PIK3CA PDCD1 HRAS CTLA4 CDKN2A
47 11.4 PIK3CA KRAS HRAS
48 11.39 PIK3CA HRAS EGFR
49 11.3 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
50 11.28 PIK3CA KRAS HRAS

GO Terms for Anus Cancer

Cellular components related to Anus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.4 PDCD1 CTLA4 CD8A CD4 CD274 CCR6

Biological processes related to Anus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell receptor signaling pathway GO:0050852 9.56 PIK3CA HRAS CTLA4 CD8A
2 Ras protein signal transduction GO:0007265 9.23 TP53 KRAS HRAS CDKN2A

Sources for Anus Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....